Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729

Bibliography

• Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253(1):239-54
   PubMed Web of Science ®Google Scholar
• Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 2011;10(8):563-4
   PubMed Web of Science ®Google Scholar
• Liu L, Puri KD, Penninger JM, Kubes P. Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo. Blood 2007;110(4):1191-8
   PubMedGoogle Scholar
• Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 2011;23(4):603-8
   PubMed Web of Science ®Google Scholar
• Rückle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’? Nat Rev Drug Discov 2006;5(11):903-18
   PubMed Web of Science ®Google Scholar
• Cushing TD, Metz DP, Whittington DA, McGee LR. PI3Kdelta and PI3Kgamma as targets for autoimmune and inflammatory diseases. J Med Chem 2012;55(20):8559-81
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee HK, Hayflick JS, et al. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006;20(3):455-65
   PubMed Web of Science ®Google Scholar
• Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009;328(3):758-65
   PubMed Web of Science ®Google Scholar
• To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182(7):897-904
   PubMed Web of Science ®Google Scholar
• Marwick JA, Caramori G, Casolari P, et al. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010;125(5):1146-53
   PubMed Web of Science ®Google Scholar
• Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Patent 2011;21(11):1773-90
   PubMed Web of Science ®Google Scholar
• Infinity Pharmaceuticals, Investor Presentation, 2013
   Google Scholar
• Hamblin N. Discovery of potent and selective PI3K delta inhibitors for the treatment of respiratory indications, MEDI 10. 245th ACS National Meeting; Spring, 2013
   Google Scholar
• Respivert Ltd. Compounds. WO2011048111; 2011
   Google Scholar
• Respivert Ltd. Quinazolin-4(3H)-one derivatives used as PI3 kinase inhibitors. WO2012052753; 2012
   Google Scholar
• Respivert Ltd. Crystalline PI3 kinase inhibitors. WO2013136076; 2013
   Google Scholar
• Clinicaltrials.gov. A study to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of RV1729, NCT01813084. 2013
   Google Scholar
• Ueda K, Kimura G, Kusama T, et al. Effects of RV1729, a phosphoinositide-3-kinase delta and gamma inhibitor, on steroid insensitive airway inflammation in tobacco-smoke exposed mice. Available from: ajrccm-conference. 2013.187.1_MeetingAbstracts.A1498
   Google Scholar
• Kizawa Y, Kimura G, Ueda K, Ito K. Effects of RV1729, a phosphoinositide-3-kinase delta and gamma inhibitor, on steroid insensitive airway inflammation in tobacco-smoke and allergen challenged mice. Available from: ajrccm-conference.2013.187.1_MeetingAbstracts.A3878
   Google Scholar
• Kimura G, Ueda K, Masuko T, et al. Effects of RV1729, a phosphoinositide-3-kinase delta and gamma inhibitor, on steroid insensitive airway inflammation in poly(I:C) challenged mice. Available from: ajrccm-conference.2013.187.1_MeetingAbstracts.A2166
   Google Scholar
• Ito K, Coates M, Murray J, et al. Effects of RV1729, a phosphoinositide 3 kinase delta and gamma inhibitor, on TNFalpha-induced CXCL8 release in peripheral blood neutrophils obtained from patients with COPD. Available from: ajrccm-conference.2013.187.1_MeetingAbstracts.A1499
   Google Scholar
• Clinicaltrials.gov. A study to evaluate the safety, tolerability and pharmacokinetics of single and repeat doses of the dry powder formulation of GSK2269557 in healthy subjects, NCT01762878. 2013
   Google Scholar
• Wilson R, Cahn A, Deans A, et al. Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase delta inhibitor (PI3Kdelta), GSK2269557, administered to healthy male subjects in a phase I study. Eur Respir J 2013;42(Suppl):136S
   Google Scholar
• See Gilead Calistoga LLC. Compositions and methods of treating a disease with (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile. WO2013116562; 2013
   Google Scholar